Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy

Purpose: To evaluate efficacy of eplerenone therapy vs. observation on resolution subretinal fluid (SRF) in patients with acute and chronic central serous chorioretinopathy (CSCR) routine clinical practice. Methods: Retrospective comparative case series eyes diagnosed CSCR treated or observation. Primary outcome measure was maximum height SRF at 12 months. Secondary percentage complete SRF, reduction ≥50%, best corrected visual acuity (VA) Separate analysis conducted for CSCR. Results: Sixty-eight 60 (82% male) were included. Eleven the 38 CSCR, seven 30 received eplerenone. Subretinal decreased from baseline to months (287 ± 221 31 63 µm) (148 134 40 42 Kaplan-Meier curves similar observed COX regression did not show a significant difference (p = 0.6 acute, p 0.2 CSCR). Conclusion: This practice study evidence nor